Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q1 2022 · 10-Q
Revenue$11.36M$11.36M+56.7% vs Q1 2021 Net Income-$14.01M-$14.01MN/M vs Q1 2021 EPS Diluted-$0.36-$0.36N/M vs Q1 2021 Operating Income-$14,220,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
Free Cash Flowderived-$20,048,000N/M Margins · derivedOperating margin-125.2%+0.9 pt vs Q1 2021
Net margin-123.4%+1.1 pt vs Q1 2021
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end